The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. While methodological changes may have affected the result, the dip highlights a period when drugmakers trimmed their pipelines and cut the number of new projects starting development. Citeline, which has tracked global drug development since the 1980s, has witnessed decades of growth in the number of drugs in development. The figures cover everything from new molecules in preclin...